CJC-1295 DAC (5mg)

CJC-1295 DAC (5mg) Peptide

CJC-1295 DAC is a synthetic, 29-amino-acid analog of Growth Hormone-Releasing Hormone (GHRH). As the shortest functional analog of GHRH, it retains the complete capacity to trigger growth hormone (GH) release from pituitary somatotroph cells while incorporating structural modifications that vastly extend its lifespan in research models. [1]

By integrating Drug Affinity Complex (DAC) technology, this peptide binds to plasma proteins (specifically albumin), extending its research half-life to approximately 8 days—a massive leap from the standard 30-minute half-life of non-DAC formulations. [2]

Core Research Areas

• Fat Loss & Body Composition: Research suggests it aids in the reduction of fat mass by mobilizing fat cells for energy.

• Lean Muscle Support: Promotes protein synthesis, potentially leading to increased muscle mass tissue hypertrophy.

• Bone and Joint Density: By promoting growth hormone levels, it may support bone growth and reinforce joint and connective tissues. [9]

• Deep Sleep Optimization: Studies indicate GHRH analogs may mirror natural sleep-center activation in the nervous system to support restorative sleep cycles. [4]

Chemical Specifications

• Molecular Formula: $C_{152}H_{252}N_{44}O_{42}$

• Molecular Weight: 3367.95 g/mol

• Synonyms: Tetrasubstituted GRF 1-29 with DAC, DAC:GRF, Long-Acting GHRH Analog

Key Scientific Findings & Mechanism of Action

1. Extended GH and IGF-1 Elevation

In landmark 2006 clinical studies, exposure to CJC-1295 DAC demonstrated a profound, dose-dependent increase in baseline growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels:

• Mean GH levels increased 2-to-10-fold for up to 6 days post-administration. [5]

• Mean IGF-1 levels increased 1.5-to-3-fold, remaining elevated for 9 to 11 days following a single exposure, and up to 28 days with repeated exposure. [5]

2. Preserved GH Pulsatility

Further research established that while CJC-1295 DAC provides continuous GHRH receptor stimulation, it does not blunt natural GH pulses. It maintains normal physiological pulsatility while boosting mean GH secretion and IGF-1 levels by roughly 50%, with peak GH levels spiking up to 7.5 times baseline. [6]

3. Structural Resistance to Degradation

Standard GHRH degrades in minutes. CJC-1295 DAC features four specific amino acid substitutions (at positions 2, 8, 15, and 27) explicitly engineered to resist enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4): [10]

4. Animal Model Benchmarks

In murine models with deleted GHRH genes (GHRHKO), daily or interval-based exposure to CJC-1295 DAC completely normalized physical growth. The compound successfully preserved lean mass and prevented the accumulation of subcutaneous fat compared to untreated control subjects. [9]

Product Note: CJC-1295 DAC peptide is manufactured and supplied strictly for research and laboratory purposes only. It is not intended for human consumption. Please review and adhere to our Terms and Conditions before finalizing your order.

References

1. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide… Drug Testing and Analysis. 2010.

2. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor… Endocrinology. 2005.

3. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues… Transl Androl Urol. 2020.

4. Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997.

5. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295… J Clin Endocrinol Metab. 2006.

6. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295… J Clin Endocrinol Metab. 2006.

7. Martin B, et al. Class II G protein-coupled receptors and their ligands in neuronal function. Neuromolecular medicine. 2005.

8. Newton AC, et al. Second Messengers. Cold Spring Harbor perspectives in biology. 2016.

9. Alba M, et al. Once-daily administration of CJC-1295… normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006.

10. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295. Subst Use Misuse. 2016.

Medical Reviewer: Dr. Marinov (MD, Ph.D.), chief assistant professor in preventative medicine & public health, specializing in peptide therapy research.